ASELL, LLC

ASELL, LLC specializes in advanced biotechnology research and scientific consulting focused on biodosimetry systems and high-throughput diagnostic technologies. The company delivers end-to-end development, validation, and regulatory pathway support for point-of-care medical devices, with demonstrated expertise in FDA clearance processes for radiation biodosimetry platforms. Their technical capabilities encompass assay development, analytical validation, clinical data analysis, and regulatory strategy formulation for diagnostic tools used in mass casualty event response and radiation exposure assessment. ASELL’s differentiation lies in its focused application of translational science to bridge laboratory innovation with operational readiness in public health emergency scenarios, ensuring compliance with stringent federal medical device standards. The contractor has established a consistent relationship with the Department of Health and Human Services, delivering scientific and technical services aligned with public health preparedness and medical countermeasure development. Their work for HHS centers on advancing biodosimetry diagnostics for use in national response frameworks, supporting both R&D and implementation-phase consulting to enhance the speed and accuracy of radiation exposure triage. ASELL operates primarily within NAICS 541714 (biotechnology R&D) and 541690 (scientific consulting), positioning itself at the intersection of biomedical innovation and regulatory science. The firm specializes in diagnostic systems for radiation biodosimetry—a niche requiring deep expertise in molecular biology, signal processing, and FDA 510(k) or de novo submission pathways. This focus establishes ASELL as a targeted provider for federal agencies developing rapid-response medical technologies. As a small business structured as 2K and headquartered in Owings Mills, Maryland, ASELL maintains a lean, mission-driven operational model. While currently holding no formal government certifications, its geographic proximity to federal health and research institutions enhances its ability to collaborate closely with HHS programs and national laboratories. The company’s market positioning reflects a strategic emphasis on high-impact, low-volume scientific contracts requiring precision, regulatory rigor, and rapid execution.